UK's IP Group 2025 NAV/share rises 13% on Pfizer royalty gains

IP

17/03/2026 07:09

Overview

UK science and tech investor's 2025 NAV/share rose 13%, driven by Pfizer Metsera royalty gains

Company reported £66.9m profit for 2025, reversing prior year's loss

Completed £75m buyback, retiring 9% of share capital in the year

Outlook

IP Group targets over £250m of exits between 2025 and end 2027

Company expects milestone and clinical trial readouts in HealthTech portfolio over next 18 months

IP Group says environment for high-growth science and technology businesses remains supportive

Result Drivers

PFIZER METSERA ROYALTY - Recognition of discounted value of future royalty and milestone income from Pfizer's acquisition of Metsera drove NAV growth

EXIT PROCEEDS - Cash realisations from exits, including Hinge Health IPO and Monolith sale, contributed to profit and liquidity

SHARE BUYBACKS - Buyback programme reduced share count, supporting NAV per share

Company press release: ID:nRSQ8734Wa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Asset Value
GBP 975.10 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the investment management & fund operators peer group is "buy"

Wall Street's median 12-month price target for IP Group PLC is GBp101.50, about 106.1% above its March 16 closing price of GBp49.25

The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 11 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)